公开(公告)号：US08642552B2

公开(公告)日：2014-02-04

申请号：US12443837

申请日：2007-10-01

申请人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

发明人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

IPC分类号： A61P25/02 ,  A61K38/18 ,  C07K14/485

CPC分类号： A61K38/1808 ,  A61K9/16 ,  C07K14/485 ,  Y10S930/12

摘要： The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.

摘要翻译： 本发明涉及人类药物和表皮生长因子（EGF）用于制备药物组合物的用途，所述药物组合物通过渗透到神经节和/或树干的周围而在疼痛的感觉运动神经病变中用于外周神经的形态功能恢复 以及缺血性神经炎的表现。 本发明还包括含有EGF的组合物，其可以与麻醉剂或止痛剂一起配制或包封在微球体中，以及其用于在疼痛敏感性运动型糖尿病性神经病变中的周围神经的形态功能恢复和缺血性神经炎的表现的用途。

公开(公告)号：US08535657B2

公开(公告)日：2013-09-17

申请号：US12092440

申请日：2006-10-27

申请人： Iraldo Bello Rivero ,  Pedro Lopez Saura ,  Yanelda Garcia Vega ,  Hector Santana Milian ,  Ana Aguilera Barreto ,  Rolando Paez Meireles ,  Lorenzo Anasagasti Angulo

发明人： Iraldo Bello Rivero ,  Pedro Lopez Saura ,  Yanelda Garcia Vega ,  Hector Santana Milian ,  Ana Aguilera Barreto ,  Rolando Paez Meireles ,  Lorenzo Anasagasti Angulo

IPC分类号： A61K38/21 ,  A61K38/00

CPC分类号： A61K38/21 ,  A61K9/19 ,  A61K38/217 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K2300/00

摘要： The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.

摘要翻译： 本发明涉及通过肠胃外（液体或冷冻干燥）或主题方式（凝胶，无油或乳膏）施用的稳定的药物制剂，其含有不同量的重组干扰素γ和α的协同比例用于治疗 考虑组织或器官中细胞恶性或良性不生理生长的病理事件。

公开(公告)号：US20130224313A1

公开(公告)日：2013-08-29

申请号：US13700286

申请日：2011-05-31

申请人： Maribel Guerra Vallespi ,  Julio Raúl Fernández Massó ,  Alexis Musacchio Lasa ,  Jeovanis Gil Valdés ,  Osvaldo Reyes Acosta ,  Brizaida Maylin Oliva Argüelles

发明人： Maribel Guerra Vallespi ,  Julio Raúl Fernández Massó ,  Alexis Musacchio Lasa ,  Jeovanis Gil Valdés ,  Osvaldo Reyes Acosta ,  Brizaida Maylin Oliva Argüelles

IPC分类号： A61K38/10 ,  A61K31/513 ,  A61K33/24 ,  G01N33/574 ,  A61K48/00 ,  C07K7/08

CPC分类号： C12N15/11 ,  A61K31/505 ,  A61K31/513 ,  A61K33/24 ,  A61K38/10 ,  A61K38/1767 ,  A61K45/06 ,  A61K48/00 ,  C07K7/08 ,  G01N33/574 ,  A61K2300/00

摘要： This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

摘要翻译： 本发明描述了通过增加与降低或阻断癌细胞增殖相关的COMMD1蛋白的核定位来治疗癌症的方法。 本发明还涉及在制造用于癌症治疗的药物中增加COMMD1蛋白的核定位的试剂的用途。 这些试剂可以是其他化合物中的肽或蛋白质。 本发明还涉及来自序列HARIKPTFRRLKWKKYKGKFW的肽的优化，以增加蛋白质COMMD的核定位，从而提高该肽的抗肿瘤效果。

公开(公告)号：US08431524B2

公开(公告)日：2013-04-30

申请号：US13120855

申请日：2009-09-30

申请人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enríque Guillen Nieto

发明人： Alicia Santos Savio ,  Osvaldo Reyes Acosta ,  Haydee Geronimo Perez ,  Hilda Elisa Garay Perez ,  Yunier Rodriguez Alvarez ,  Gerardo Enríque Guillen Nieto

IPC分类号： A61K38/04 ,  C12Q1/68

CPC分类号： C07K14/5443 ,  A61K38/00

摘要： The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor α subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

摘要翻译： 本发明涉及分子免疫学领域，特别涉及衍生自白介素-15（IL-15）序列的肽，其中所述肽被优化以抑制该分子的生物学活性。 在本发明中，显示该肽抑制IL-15诱导的T细胞增殖，肿瘤坏死因子α（TNFalpha）诱导和IL-8受体α亚基（IL）的IL-8和IL-6的表达 -15Rα），所有这些作用由肽与IL-15Rα的结合介导。 本发明还涉及使用肽来治疗其中IL-15或IL-15Rα异常表达与疾病进程如类风湿性关节炎（RA）和前列腺癌相关的病理学。

公开(公告)号：US08105606B2

公开(公告)日：2012-01-31

申请号：US13094287

申请日：2011-04-26

申请人： Lisset Hermida Cruz ,  Rayner Rodriguez Diaz ,  Laura Lazo Vazquez ,  Aida Zulueta Morales ,  Carlos Lopez Abarrategui ,  Iris Valdes Prado ,  Ricardo de la C. Silva Rodriguez ,  Glay Chinea Santiago ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzman Tirado ,  Beatriz de la Caridad Sierra Vazquez ,  Raul Rafael Espinosa Perez

发明人： Lisset Hermida Cruz ,  Rayner Rodriguez Diaz ,  Laura Lazo Vazquez ,  Aida Zulueta Morales ,  Carlos Lopez Abarrategui ,  Iris Valdes Prado ,  Ricardo de la C. Silva Rodriguez ,  Glay Chinea Santiago ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzman Tirado ,  Beatriz de la Caridad Sierra Vazquez ,  Raul Rafael Espinosa Perez

IPC分类号： A61K39/12 ,  C07K19/00 ,  C12Q1/70

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N9/0006 ,  C12N2770/24122 ,  Y02A50/386

摘要： The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

摘要翻译： 本发明涉及获得编码蛋白质的蛋白质的嵌合链，其能够在受体中诱导抗登革病毒感染的血清型特异性和保护性体液免疫应答，从而消除血清型非特异性病毒免疫增强的作用 导致这种病理描述的出血和临床并发症。 核酸的这些嵌合链由来自脑膜炎奈瑟氏球菌与脱氢酶活性的突变蛋白质的基因的片段的特异性组合和编入来自登革病毒的包膜（E）蛋白的区域的片段组成，当插入时 表达载体，产生具有特定性质的嵌合蛋白。 所得到的本发明的嵌合分子适用于获得用于人类的疫苗制剂和高血清型特异性的诊断方法的制药工业。

公开(公告)号：US08076297B2

公开(公告)日：2011-12-13

申请号：US11631880

申请日：2005-07-05

申请人： Maria del Carmen Abrahantes Pérez ,  Jesús Reyes González ,  Gloria Véliz Rios ,  Eduardo Martinez Diaz ,  Caridad Anais Gasmuri González ,  José Garcia Suárez ,  Mónica Bequet Romero ,  Luis Javier González López ,  Lila Rosa Castellanos Serra ,  Manuel Selman-Housein Sosa ,  Raúl Gómez Riera ,  Jorge Victor Gavilondo Cowley

发明人： Maria del Carmen Abrahantes Pérez ,  Jesús Reyes González ,  Gloria Véliz Rios ,  Eduardo Martinez Diaz ,  Caridad Anais Gasmuri González ,  José Garcia Suárez ,  Mónica Bequet Romero ,  Luis Javier González López ,  Lila Rosa Castellanos Serra ,  Manuel Selman-Housein Sosa ,  Raúl Gómez Riera ,  Jorge Victor Gavilondo Cowley

IPC分类号： A61K38/43 ,  C12N9/52

CPC分类号： A61K38/16

摘要： The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.

摘要翻译： 本发明涉及能够抑制不同组织起源的肿瘤细胞和活化的内皮细胞的生长的组合物。 所述组合物的组分是对应于来自分子末端的内部甲硫氨酸的对应于C-末端片段的血清素的多肽片段，其可以在它们之间并且任选地与促进组合物的抗肿瘤作用的催乳素蛋白质组合 。 组合物中的生殖细胞可以是0.1-100nM的浓度。 该组合物的抗增殖作用由凋亡机制介导。 “体内”治疗对恶性肿瘤具有抗肿瘤，抗血管生成和保护作用。

公开(公告)号：US20110200628A1

公开(公告)日：2011-08-18

申请号：US13094287

申请日：2011-04-26

申请人： Lisset Hermida Cruz ,  Rayner Rodriguez Diaz ,  Laura Lazo Vazquez ,  Aida Zulueta Morales ,  Carlos Lopez Abarrategui ,  Iris Valdes Prado ,  Ricardo de la C. Silva Rodriguez ,  Glay Chinea Santiago ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzman Tirado ,  Beatriz de la Caridad Sierra Vazquez ,  Raul Rafael Espinosa Perez

发明人： Lisset Hermida Cruz ,  Rayner Rodriguez Diaz ,  Laura Lazo Vazquez ,  Aida Zulueta Morales ,  Carlos Lopez Abarrategui ,  Iris Valdes Prado ,  Ricardo de la C. Silva Rodriguez ,  Glay Chinea Santiago ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzman Tirado ,  Beatriz de la Caridad Sierra Vazquez ,  Raul Rafael Espinosa Perez

IPC分类号： A61K39/12 ,  C07K14/18 ,  A61P31/12 ,  A61P37/04

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N9/0006 ,  C12N2770/24122 ,  Y02A50/386

摘要： The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

摘要翻译： 本发明涉及获得编码蛋白质的蛋白质的嵌合链，其能够在受体中诱导抗登革病毒感染的血清型特异性和保护性体液免疫应答，从而消除血清型非特异性病毒免疫增强的作用 导致这种病理描述的出血和临床并发症。 核酸的这些嵌合链由来自脑膜炎奈瑟氏球菌与脱氢酶活性的突变蛋白质的基因的片段的特异性组合和编入来自登革病毒的包膜（E）蛋白的区域的片段组成，当插入时 表达载体，产生具有特定性质的嵌合蛋白。 所得到的本发明的嵌合分子适用于获得用于人类的疫苗制剂和高血清型特异性的诊断方法的制药工业。

公开(公告)号：US20100316669A1

公开(公告)日：2010-12-16

申请号：US12430534

申请日：2009-04-27

申请人： Santiago Duenas Carrera ,  Juan Morales Grillo ,  Liz Alvarez-Lajonchere Ponce de Leon ,  Alexis Musacchio Lasa ,  Rolando Pajon Feyt ,  Ariel Vina Rodriguez ,  Julio C. Alvarez Obregon ,  Nelson Acosta Rivero ,  Gillian Martinez Donato

发明人： Santiago Duenas Carrera ,  Juan Morales Grillo ,  Liz Alvarez-Lajonchere Ponce de Leon ,  Alexis Musacchio Lasa ,  Rolando Pajon Feyt ,  Ariel Vina Rodriguez ,  Julio C. Alvarez Obregon ,  Nelson Acosta Rivero ,  Gillian Martinez Donato

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/295 ,  A61P31/14 ,  A61P31/20

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/24234

摘要： Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens.These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

摘要翻译： 包含作为主要成分的疫苗抗原的制剂：a-）在免疫个体中表达一种或几种蛋白质的一种或几种DNA，和b-以适当比例的病毒抗原。 开发新的配方，最大限度地减少增加和多样化针对不同病原体的免疫反应谱的组分数量，并产生抗病原体的联合疫苗。 这些制剂可以应用于制药工业中用于预防和/或治疗人类。

公开(公告)号：US07799760B2

公开(公告)日：2010-09-21

申请号：US12197001

申请日：2008-08-22

申请人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Berlanga Acosta ,  Jose I. Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Franco Perez ,  Ingrid Rojas Constantin ,  Hector Santana Milian ,  Larissa Chacon Corvea ,  Gerardo E. Guillen Nieto ,  Luis Herrera Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K38/18 ,  C07K14/485

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，（ii）皮肤缺血性损伤的瘢痕形成，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以瘢痕和/或愈合的溃疡或其他损伤。

公开(公告)号：US20080254050A1

公开(公告)日：2008-10-16

申请号：US11787522

申请日：2007-04-17

申请人： Monica Bequet Romero ,  Boris Ernesto Acevedo Castro ,  Jorge Victor Gavilondo Cowley ,  Luis Enrique Fernandez Molina ,  Omar Lopez Ocejo ,  Ricardo de la Caridad Silva Rodriguez ,  Alexis Musachio Lasa ,  Ernesto Galban Rodriguez ,  Dania Marcia Vazquez Blomquist

发明人： Monica Bequet Romero ,  Boris Ernesto Acevedo Castro ,  Jorge Victor Gavilondo Cowley ,  Luis Enrique Fernandez Molina ,  Omar Lopez Ocejo ,  Ricardo de la Caridad Silva Rodriguez ,  Alexis Musachio Lasa ,  Ernesto Galban Rodriguez ,  Dania Marcia Vazquez Blomquist

IPC分类号： A61K39/00 ,  A61P37/00

CPC分类号： C07K14/715 ,  A61K38/1858 ,  A61K38/1866 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/0011 ,  A61K48/005 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55594 ,  C07K14/515 ,  C07K14/52 ,  C07K14/71

摘要： Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.

摘要翻译： 血管通透性因子（VPF）家族的分子的寡核苷酸和多肽序列在病理实体的主动免疫治疗中的应用及其修饰，其中该过程与增加相关 血管生成。 这些方法可以用于治疗癌症及其转移，急性和慢性炎症过程，感染性疾病，自身免疫性疾病，糖尿病和新生儿视网膜病变，器官移植排斥，黄斑变性，新生血管性青光眼，血管瘤和 血管纤维瘤等。